Agile Therapeutics
AGRX
AGRX was delisted on the 25th of March, 2024.
21 hedge funds and large institutions have $496K invested in Agile Therapeutics in 2023 Q4 according to their latest regulatory filings, with 5 funds opening new positions, 6 increasing their positions, 3 reducing their positions, and 1 closing their positions.
400% more first-time investments, than exits
New positions opened: 5 | Existing positions closed: 1
100% more repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 3
40% more capital invested
Capital invested by funds: $355K → $496K (+$141K)
24% more funds holding
Funds holding: 17 → 21 (+4)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
+$119K |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$41.2K |
| 3 |
AC
Armistice Capital
New York
|
+$20.1K |
| 4 |
Citadel Advisors
Miami,
Florida
|
+$12.9K |
| 5 |
JP Morgan Chase
New York
|
+$8.53K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
-$593 |
| 2 |
Geode Capital Management
Boston,
Massachusetts
|
-$84 |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
-$2 |
| 4 |
Osaic Holdings
Scottsdale,
Arizona
|
-$2 |
AGRX Hedge Fund Activity: Q4 2023 in Review
21 of the 6,869 institutional investors tracked by Wall St. Rank reported a position in Agile Therapeutics (AGRX) for Q4 2023, worth a combined $496K — up 40% from $355K a quarter earlier.
Buyers outnumbered sellers: 5 funds opened new AGRX positions and 1 closed out — a net gain of 4 holders — while 6 added to existing stakes and 3 trimmed.
The largest buyer was Renaissance Technologies, opening a new position worth an estimated $119K. The largest seller was BlackRock, cutting an estimated $593.
- 21 institutional investors held Agile Therapeutics (AGRX) as of Q4 2023, up from 17 in Q3 2023.
- Funds reported $496K of Agile Therapeutics stock for Q4 2023, up 40% quarter-over-quarter.
- 5 funds opened new Agile Therapeutics positions in Q4 2023 and 1 closed out, a net change of +4 holders.
- The largest Agile Therapeutics buyer in Q4 2023 was Renaissance Technologies, an estimated $119K added.
- The largest Agile Therapeutics seller in Q4 2023 was BlackRock, an estimated $593 sold.
Based on aggregated 13F filings for Q4 2023.